Source comparison
Comparison: TB-500 vs. BPC-157 vs. Standard Post-ACL Protocols
Mechanism Actin regulation, collagen deposition, angiogenesis Vascular endothelial growth factor upregulation, nitric oxide signaling Physical therapy, NSAIDs, time TB-500 targets structural collagen repair directly. BPC-157 focuses on vascular supply. Both of
This comparison does not assign a generated winner or score.
- Mechanism
- Actin regulation, collagen deposition, angiogenesis
- Vascular endothelial growth factor upregulation, nitric oxide signaling
- Physical therapy, NSAIDs, time
- TB-500 targets structural collagen repair directly. BPC-157 focuses on vascular supply. Both offer mechanisms standard rehab doesn't address.
- Collagen Type I Increase
- 42% greater deposition (rat tendon study)
- 30–35% (estimated from wound healing models)
- Baseline rate only
- TB-500 shows the largest documented effect on type I collagen specifically.
- Inflammatory Modulation
- Reduces TNF-alpha, IL-1beta, IL-6 without blocking cascade
- Reduces mast cell infiltration, stabilizes cellular response
- NSAIDs suppress broadly
- TB-500 modulates inflammation more selectively than NSAIDs.
- Optimal Treatment Window
- 0–28 days post-injury for maximum effect
- 0–14 days (earlier is better)
- Begins immediately
- Both peptides require early administration. Delayed use shows minimal benefit.
- Research Grade Availability
- Widely available from licensed suppliers
- Widely available but less standardized
- N/A
- Purity and sequencing verification are essential for reproducible outcomes with both peptides.